The Nanosonics (ASX: NAN) AGM 2023 Flags Softer Sales Conditions
The Nanosonics (ASX: NAN) AGM reveals challenging conditions for the hospital industry but management is buoyed by CORIS progress.
Nanosonics (ASX: NAN)
Nanosonics (ASX: NAN) is a healthcare company that specialises in developing and manufacturing innovative medical devices. Nanosonics’ main product, launched in 2009, is the Trophon EPR, a machine that automatically performs and documents high level disinfection on ultrasound probes. However, it also plans to launch a new product for endoscope disinfection.
Nanosonics makes money by selling both Trophon devices but also the proprietary hydrogen peroxide NanoNebulant capsules consumed in each disinfection cycle. This means each sale of a device is accompanied by ongoing revenue linked to usage of the device, sometimes called a razor plus blade business model.
Nanosonics (ASX: NAN) H1 FY 2023 Results: Record Revenue
The Nanosonics (ASX: NAN) H1 FY 2023 results saw record revenue, improving margins and positive free cash flow.
5 ASX Stocks With Positive 2022 AGM Updates
These 5 ASX small-cap companies all disclosed continuing growth in their AGM presentations, providing a good opportunity to check in on the thesis.
Nanosonics (ASX: NAN) Results FY 2022 And Reflections On Competition Risk
The FY 2022 Nanosonics results show revenue growth but net profit lower, due to building out the direct sales function.
My Blueprint for Understanding Nanosonics (ASX: NAN) Shares In The Next Two Years
Nanosonics (ASX: NAN) has a poor short term outlook but the very high short interest may create a tasty opportunity down the track.
Nanosonics (ASX: NAN) Share Price Falls On Market Update
Nanosonics shares dropped this morning when it updated the market on its half year revenue, and its distribution agreement with GE Healthcare.
Baby Giants Podcast On Omicron Strain And Nanosonics
Claude Walker, Matt Joass, Andrew Page, and Kevin Fung discuss Nanosonics stock and the impact of omicron on investors.
Nanosonics (ASX: NAN) Results FY 2021: The Re-Stonkification
The Nanosonics share price is up over 20% on results, thanks to a much stronger second half. So is it time to take profits?
Claude Chats Nanosonics and Xero On The Call
In this video, I explain why I’m currently accumulating Nanosonics shares…
3 Already Profitable Fluffy Dogs I’d Like To Buy In A Drawdown
These 3 stocks remained profitable throughout the pandemic, are positioned for a stronger 2021, and are not too far from attractive value…
Nanosonics (ASX:NAN) Share Price Takes A Hit On Pandemic Impact
The Nanosonics share price dived today on a weak first half revenue result, but the future may look brighter.
Updated Fluffy Dogs Watchlist For Buying In Recession
Removing a few companies and adding 6 more…
Nanosonics (ASX: NAN) 1H FY 2020 Results Show Steady Progress, But No Reason To Buy
It’s steady as she goes for Nanosonics in the 1st half of FY 2020, but that won’t be enough for an optimistic market…